Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yttrium-90-labeled anti-CEA antibody
- Development stage
- Unknown
- Lead developer
- City of Hope
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Yttrium-90-labeled anti-CEA antibody is a radiolabeled monoclonal antibody therapy designed for targeted radioimmunotherapy of cancers expressing carcinoembryonic antigen (CEA). The drug consists of a humanized or chimeric monoclonal antibody that specifically binds to CEA on tumor cells and is conjugated to the radioactive isotope yttrium-90 via a chelator such as DOTA or DTPA. Upon binding to CEA-expressing cells, the beta-emitting yttrium-90 delivers localized radiation intended to destroy malignant cells while sparing surrounding healthy tissue. Several variants exist based on the specific mAb used (e.g., M5A, hMN-14/labetuzumab, cT84.66). This approach has been investigated primarily in advanced solid tumors such as colorectal cancer and medullary thyroid cancer[1][2][3][6]. The mechanism combines targeted immunotherapy with radiopharmaceutical cytotoxicity.
- Other names
- yttrium Y 90-DOTA anti-CEA monoclonal antibody M5Ayttrium Y 90 anti-CEA monoclonal antibody cT84.6690Y-labeled anti-caricnoembryonic antigen monoclonal antibody
Beyond the preview
Go deeper on yttrium-90-labeled anti-CEA antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yttrium-90-labeled anti-CEA antibody.